300149 睿智医药
交易中 03-03 09:47:36
资讯
新帖
简况
睿智医药：目前公司定增项目仍在审批中
证券之星 · 02-27
睿智医药：目前公司定增项目仍在审批中
睿智医药：截至2026年2月13日，公司股东人数为36,369人
证券之星 · 02-25
睿智医药：截至2026年2月13日，公司股东人数为36,369人
睿智医药：截至2026年2月13日，公司股东人数为36,369人
证券之星 · 02-25
睿智医药：截至2026年2月13日，公司股东人数为36,369人
股市必读：睿智医药(300149)股东户数3.7万户，较上期减少1%
证券之星 · 02-24
股市必读：睿智医药(300149)股东户数3.7万户，较上期减少1%
睿智医药：截止至2026年2月10日，公司股东人数为37,038人
证券之星 · 02-13
睿智医药：截止至2026年2月10日，公司股东人数为37,038人
睿智医药(300149)1月30日股东户数3.74万户，较上期减少0.6%
证券之星 · 02-09
睿智医药(300149)1月30日股东户数3.74万户，较上期减少0.6%
睿智医药：截至1月30日，公司的股东人数为37,414人
证券之星 · 02-04
睿智医药：截至1月30日，公司的股东人数为37,414人
股市必读：睿智医药（300149）预计2025年全年扣非后净利润亏损250万元至375万元
证券之星 · 02-02
股市必读：睿智医药（300149）预计2025年全年扣非后净利润亏损250万元至375万元
股市必读：睿智医药(300149)股东户数3.76万户，较上期减少3.57%
证券之星 · 01-30
股市必读：睿智医药(300149)股东户数3.76万户，较上期减少3.57%
睿智医药：公司在股权激励计划中所设定的业绩目标
证券之星 · 01-29
睿智医药：公司在股权激励计划中所设定的业绩目标
股市必读：1月28日睿智医药现1笔折价17.63%的大宗交易 合计成交247.06万元
证券之星 · 01-29
股市必读：1月28日睿智医药现1笔折价17.63%的大宗交易 合计成交247.06万元
睿智医药（300149）披露为子公司提供担保进展，1月22日股价下跌1.02%
证券之星 · 01-22
睿智医药（300149）披露为子公司提供担保进展，1月22日股价下跌1.02%
睿智医药(300149)1月10日股东户数3.9万户，较上期增加4.43%
证券之星 · 01-19
睿智医药(300149)1月10日股东户数3.9万户，较上期增加4.43%
睿智医药：西部证券、灏霁资产等多家机构于1月15日调研我司
证券之星 · 01-16
睿智医药：西部证券、灏霁资产等多家机构于1月15日调研我司
睿智医药(300149.SZ)两股东拟减持合计不超6%股份
智通财经 · 01-15
睿智医药(300149.SZ)两股东拟减持合计不超6%股份
股市必读：睿智医药(300149)股东户数3.74万户，较上期减少3.07%
证券之星 · 01-08
股市必读：睿智医药(300149)股东户数3.74万户，较上期减少3.07%
睿智医药：超限智造助力ADC及小核酸药物研发
证券之星 · 01-07
睿智医药：超限智造助力ADC及小核酸药物研发
每周股票复盘：睿智医药（300149）股东户数减少1.92%
证券之星 · 01-03
每周股票复盘：睿智医药（300149）股东户数减少1.92%
睿智医药：公司生产经营活动一切正常
证券之星 · 2025-12-25
睿智医药：公司生产经营活动一切正常
睿智医药（300149）披露关联方对全资子公司增资进展暨完成工商登记，12月22日股价上涨0.2%
证券之星 · 2025-12-22
睿智医药（300149）披露关联方对全资子公司增资进展暨完成工商登记，12月22日股价上涨0.2%
加载更多
公司概况
公司名称：
睿智医药科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2010-12-22
主营业务：
睿智医药科技股份有限公司的主营业务是提供涵盖化学药研发以及生物药从早期发现到开发与规模化生产阶段的一体化服务。公司的主要产品是化学业务、药效药动业务、大分子业务。
发行价格：
28.00
{"stockData":{"symbol":"300149","market":"SZ","secType":"STK","nameCN":"睿智医药","latestPrice":10.35,"timestamp":1772502456000,"preClose":10.35,"halted":0,"volume":1342980,"delay":0,"changeRate":0,"floatShares":475000000,"shares":498000000,"eps":-0.3168,"marketStatus":"交易中","change":0,"latestTime":"03-03 09:47:36","open":10.35,"high":10.48,"low":10.33,"amount":13955600,"amplitude":0.0145,"askPrice":10.36,"askSize":279,"bidPrice":10.35,"bidSize":266,"shortable":0,"etf":0,"ttmEps":-0.3168,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1772508600000},"marketStatusCode":2,"adr":0,"adjPreClose":10.35,"symbolType":"stock","openAndCloseTimeList":[[1772501400000,1772508600000],[1772514000000,1772521200000]],"highLimit":11.39,"lowLimit":9.32,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":497963992,"isCdr":false,"pbRate":4.11,"roa":"--","roe":"0.58%","epsLYR":-0.45,"committee":-0.186972,"marketValue":5154000000,"turnoverRate":0.0028,"status":2,"floatMarketCap":4912000000},"requestUrl":"/m/hq/s/300149","defaultTab":"news","newsList":[{"id":"2614870007","title":"睿智医药：目前公司定增项目仍在审批中","url":"https://stock-news.laohu8.com/highlight/detail?id=2614870007","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614870007?lang=zh_cn&edition=full","pubTime":"2026-02-27 11:33","pubTimestamp":1772163190,"startTime":"0","endTime":"0","summary":"证券之星消息，睿智医药(300149)02月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司定增方案为何迟迟没有批复?如果证监会没有批复，公司有何应对方案?睿智医药回复：尊敬的投资者，您好！目前公司定增项目仍在审批中，后续还需深交所审核通过及获得中国证监会同意注册后方可实施。公司也在持续关注进展，并将严格按照相关法律法规的要求及时履行信息披露义务。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700016323.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0216","300149"],"gpt_icon":0},{"id":"2614251727","title":"睿智医药：截至2026年2月13日，公司股东人数为36,369人","url":"https://stock-news.laohu8.com/highlight/detail?id=2614251727","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614251727?lang=zh_cn&edition=full","pubTime":"2026-02-25 09:06","pubTimestamp":1771981568,"startTime":"0","endTime":"0","summary":"证券之星消息，睿智医药(300149)02月24日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司截日股东人数是多少？睿智医药回复：您好，感谢您对公司的关注。截至2026年2月13日，公司股东人数为36,369人。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500006350.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0216","BK0077"],"gpt_icon":0},{"id":"2614727252","title":"睿智医药：截至2026年2月13日，公司股东人数为36,369人","url":"https://stock-news.laohu8.com/highlight/detail?id=2614727252","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614727252?lang=zh_cn&edition=full","pubTime":"2026-02-25 09:06","pubTimestamp":1771981566,"startTime":"0","endTime":"0","summary":"证券之星消息，睿智医药(300149)02月24日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止到2月20日（2月13日收盘）公司的股东人数是多少？谢谢睿智医药回复：您好，感谢您对公司的关注。截至2026年2月13日，公司股东人数为36,369人。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500006347.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","BK0077","300149"],"gpt_icon":0},{"id":"2613739236","title":"股市必读：睿智医药(300149)股东户数3.7万户，较上期减少1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613739236","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613739236?lang=zh_cn&edition=full","pubTime":"2026-02-24 02:06","pubTimestamp":1771869976,"startTime":"0","endTime":"0","summary":"截至2026年2月13日收盘，睿智医药报收于10.99元，下跌0.99%，换手率1.41%，成交量6.71万手，成交额7434.48万元。交易信息汇总资金流向2月13日主力资金净流出545.89万元，占总成交额7.34%；游资资金净流出112.9万元，占总成交额1.52%；散户资金净流入658.79万元，占总成交额8.86%。股本股东变化股东户数变动近日睿智医药披露，截至2026年2月10日公司股东户数为3.7万户，较1月30日减少376.0户，减幅为1.0%。户均持股数量由上期的1.33万股增加至1.34万股，户均持股市值为15.17万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400007410.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","BK0077","300149"],"gpt_icon":0},{"id":"2611270185","title":"睿智医药：截止至2026年2月10日，公司股东人数为37,038人","url":"https://stock-news.laohu8.com/highlight/detail?id=2611270185","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611270185?lang=zh_cn&edition=full","pubTime":"2026-02-13 11:33","pubTimestamp":1770953633,"startTime":"0","endTime":"0","summary":"证券之星消息，睿智医药(300149)02月12日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘你好，请问截止至2026年2月10日收盘公司股东人数为多少，谢谢！睿智医药回复：您好，感谢对公司的关注。截止至2026年2月10日，公司股东人数为37,038人。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021300014783.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0077","BK0216"],"gpt_icon":0},{"id":"2610633071","title":"睿智医药(300149)1月30日股东户数3.74万户，较上期减少0.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610633071","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610633071?lang=zh_cn&edition=full","pubTime":"2026-02-09 17:27","pubTimestamp":1770629272,"startTime":"0","endTime":"0","summary":"证券之星消息，近日睿智医药披露，截至2026年1月30日公司股东户数为3.74万户，较1月20日减少227.0户，减幅为0.6%。在医疗服务行业个股中，睿智医药股东户数低于行业平均水平，截至1月30日，医疗服务行业平均股东户数为4.63万户。从股价来看，2026年1月20日至2026年1月30日，睿智医药区间跌幅为3.33%，在此期间股东户数减少227.0户，减幅为0.6%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020900022196.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0216","BK0077"],"gpt_icon":0},{"id":"2608336547","title":"睿智医药：截至1月30日，公司的股东人数为37,414人","url":"https://stock-news.laohu8.com/highlight/detail?id=2608336547","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608336547?lang=zh_cn&edition=full","pubTime":"2026-02-04 11:33","pubTimestamp":1770176036,"startTime":"0","endTime":"0","summary":"证券之星消息，睿智医药(300149)02月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司截止到一月底股东人数是多少？睿智医药回复：尊敬的投资者，您好！感谢对公司的关注。截至1月30日，公司的股东人数为37,414人。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400016151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0216","BK0077"],"gpt_icon":0},{"id":"2608896758","title":"股市必读：睿智医药（300149）预计2025年全年扣非后净利润亏损250万元至375万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608896758","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608896758?lang=zh_cn&edition=full","pubTime":"2026-02-02 03:26","pubTimestamp":1769973973,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，睿智医药报收于10.44元，下跌2.34%，换手率2.42%，成交量11.51万手，成交额1.21亿元。来自：2025年度非经常性损益影响金额为1,480万元至2,220万元，主要来源于出售合营公司投资收益及政府补助。业绩披露要点业绩预告睿智医药发布业绩预告，预计2025年全年扣非后净利润亏损250万元至375万元。非经常性损益影响约为1,480.00万元至2,220.00万元，主要为出售合营公司投资收益及政府补助。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200001614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149"],"gpt_icon":0},{"id":"2607705344","title":"股市必读：睿智医药(300149)股东户数3.76万户，较上期减少3.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607705344","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607705344?lang=zh_cn&edition=full","pubTime":"2026-01-30 03:43","pubTimestamp":1769715790,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，睿智医药报收于10.69元，下跌0.28%，换手率2.48%，成交量11.78万手，成交额1.26亿元。股本股东变化股东户数变动近日睿智医药披露，截至2026年1月20日公司股东户数为3.76万户，较1月10日减少1393.0户，减幅为3.57%。户均持股数量由上期的1.28万股增加至1.32万股，户均持股市值为14.29万元。董秘最新回复投资者： 董秘您好，请问公司到1月20日的股东人数，谢谢董秘： 尊敬的投资者，您好！截至1月20日，公司的股东人数为37,641人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000004081.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300149","BK0077"],"gpt_icon":0},{"id":"2607590701","title":"睿智医药：公司在股权激励计划中所设定的业绩目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2607590701","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607590701?lang=zh_cn&edition=full","pubTime":"2026-01-29 16:21","pubTimestamp":1769674870,"startTime":"0","endTime":"0","summary":"投资者提问：公司股权激励计划2027年营收25亿以上，利润2个亿。据投资者会议记录，胡瑞连董事长说长远目标是达到全世界临床前CRO业务的百分之一。感谢对公司的关注。公司在股权激励计划中所设定的业绩目标，是基于对公司过往经营积淀、目前运营状况、核心研发平台能力、市场化拓展策略以及内部运营效率提升等多方面因素的综合评估，经审慎论证后确定的。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900025831.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0216","BK0077"],"gpt_icon":0},{"id":"2607749799","title":"股市必读：1月28日睿智医药现1笔折价17.63%的大宗交易 合计成交247.06万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607749799","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607749799?lang=zh_cn&edition=full","pubTime":"2026-01-29 01:56","pubTimestamp":1769622972,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘，睿智医药报收于10.72元，下跌2.81%，换手率2.46%，成交量11.67万手，成交额1.26亿元。来自交易信息汇总：睿智医药当日出现一笔折价17.63%的大宗交易，合计成交247.06万元，引发市场关注。交易信息汇总资金流向1月28日主力资金净流出1064.33万元；游资资金净流入700.34万元；散户资金净流入364.0万元。大宗交易1月28日睿智医药现1笔折价17.63%的大宗交易，合计成交247.06万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900001132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0216","BK0077"],"gpt_icon":0},{"id":"2605949730","title":"睿智医药（300149）披露为子公司提供担保进展，1月22日股价下跌1.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605949730","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605949730?lang=zh_cn&edition=full","pubTime":"2026-01-22 22:22","pubTimestamp":1769091740,"startTime":"0","endTime":"0","summary":"截至2026年1月22日收盘，睿智医药报收于10.71元，较前一交易日下跌1.02%，最新总市值为53.33亿元。该股当日开盘10.82元，最高10.91元，最低10.69元，成交额达1.26亿元，换手率为2.47%。本次担保属于公司2025年度为子公司提供担保额度范围内，无需另行提交董事会或股东大会审议。截至公告日，公司及控股子公司担保额度总金额为90,324.82万元，实际担保余额为8,770.31万元，占公司2024年度经审计净资产的7.23%，无逾期担保。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200040780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0077","BK0216"],"gpt_icon":0},{"id":"2604184628","title":"睿智医药(300149)1月10日股东户数3.9万户，较上期增加4.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604184628","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604184628?lang=zh_cn&edition=full","pubTime":"2026-01-19 17:28","pubTimestamp":1768814908,"startTime":"0","endTime":"0","summary":"证券之星消息，近日睿智医药披露，截至2026年1月10日公司股东户数为3.9万户，较12月31日增加1657.0户，增幅为4.43%。在医疗服务行业个股中，睿智医药股东户数低于行业平均水平，截至1月10日，医疗服务行业平均股东户数为4.51万户。从股价来看，2025年12月31日至2026年1月10日，睿智医药区间涨幅为14.54%，在此期间股东户数增加1657.0户，增幅为4.43%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900023330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0077","BK0216"],"gpt_icon":0},{"id":"2603785967","title":"睿智医药：西部证券、灏霁资产等多家机构于1月15日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2603785967","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603785967?lang=zh_cn&edition=full","pubTime":"2026-01-16 19:01","pubTimestamp":1768561314,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年1月16日睿智医药发布公告称西部证券、灏霁资产、兴全基金、复胜资产于2026年1月15日调研我司。目前已经参与的有深圳市罗湖东海睿智医药产业投资基金等，公司将充分发挥“链主”作用，依托自身技术服务能力，有效整合产业链资源，协同各方构建生态闭环，实现共赢发展。目前，公司已与圣诺医药、海优生物、君健生物等多家核酸领域企业达成深度合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600033320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0216","BK0183","BK0276","BK0188","002673","BK0028","300149"],"gpt_icon":0},{"id":"2603639601","title":"睿智医药(300149.SZ)两股东拟减持合计不超6%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2603639601","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603639601?lang=zh_cn&edition=full","pubTime":"2026-01-15 19:17","pubTimestamp":1768475861,"startTime":"0","endTime":"0","summary":"智通财经APP讯，睿智医药(300149.SZ)发布公告，持股5%以上股东梁玉凤女士计划在本公告披露之日起十五个交易日后的三个月内以集中竞价或大宗交易方式减持公司股份不超过1493.89万股(占公司总股本比例3%)。持股5%以上股东于显文先生计划在本公告披露之日起十五个交易日后的三个月内以集中竞价或大宗交易方式减持公司股份不超过1493.89万股(占公司总股本比例3%)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","300149","BK0077"],"gpt_icon":0},{"id":"2601138845","title":"股市必读：睿智医药(300149)股东户数3.74万户，较上期减少3.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601138845","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601138845?lang=zh_cn&edition=full","pubTime":"2026-01-08 02:00","pubTimestamp":1767808848,"startTime":"0","endTime":"0","summary":"截至2026年1月7日收盘，睿智医药报收于10.12元，上涨0.8%，换手率2.77%，成交量13.14万手，成交额1.33亿元。交易信息汇总资金流向1月7日主力资金净流入778.03万元；游资资金净流入266.78万元；散户资金净流出1044.82万元。股本股东变化股东户数变动近日睿智医药披露，截至2025年12月31日公司股东户数为3.74万户，较12月20日减少1182.0户，减幅为3.07%。户均持股数量由上期的1.29万股增加至1.33万股，户均持股市值为12.74万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800000989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0216","BK0077"],"gpt_icon":0},{"id":"2601842131","title":"睿智医药：超限智造助力ADC及小核酸药物研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2601842131","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601842131?lang=zh_cn&edition=full","pubTime":"2026-01-07 09:12","pubTimestamp":1767748325,"startTime":"0","endTime":"0","summary":"目前基于超限智造开发的两套自动化集成式微流合成系统首先用于内部平台建设，助力客户在ADC及小核酸药物领域的研发创新，后续也将积极考量市场化延展，推进技术授权合作事宜。超限智造平台的核心优势在于高度集成化、自动化与精准的流程控制能力，在效率、环保及成本控制方面表现突出。该平台的深入应用，将助力公司夯实在ADC与小核酸两大前沿领域的技术护城河，进一步巩固并提升市场竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700005487.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300149","BK0216"],"gpt_icon":0},{"id":"2600337060","title":"每周股票复盘：睿智医药（300149）股东户数减少1.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600337060","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600337060?lang=zh_cn&edition=full","pubTime":"2026-01-03 03:29","pubTimestamp":1767382149,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，睿智医药报收于9.56元，较上周的9.68元下跌1.24%。本周，睿智医药12月29日盘中最高价报9.71元。12月31日盘中最低价报9.48元。睿智医药当前最新总市值47.61亿元，在医疗服务板块市值排名35/51，在两市A股市值排名3476/5181。股本股东变化股东户数变动截至2025年12月20日，睿智医药股东户数为3.86万户，较12月10日减少754.0户，减幅为1.92%。户均持股数量由上期的1.27万股上升至1.29万股，户均持股市值为12.67万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300002225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300149","BK0077"],"gpt_icon":0},{"id":"2594728112","title":"睿智医药：公司生产经营活动一切正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2594728112","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594728112?lang=zh_cn&edition=full","pubTime":"2025-12-25 11:34","pubTimestamp":1766633643,"startTime":"0","endTime":"0","summary":"近期注意到公司股价表现均较为低迷。股价波动受多重因素综合影响。目前公司生产经营活动一切正常，各项业务有序推进。公司将持续聚焦主业，扎实经营，努力提升核心竞争力和盈利能力，以回报广大投资者的信任。在市值管理方面，公司董事会及管理层始终高度重视市值表现与投资者关系维护。未来，公司将继续规范运作，提升经营质量，积极传递公司价值，用高质量发展回馈市场信任与投资者支持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500013607.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300149","BK0077"],"gpt_icon":0},{"id":"2593337964","title":"睿智医药（300149）披露关联方对全资子公司增资进展暨完成工商登记，12月22日股价上涨0.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593337964","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593337964?lang=zh_cn&edition=full","pubTime":"2025-12-22 22:31","pubTimestamp":1766413906,"startTime":"0","endTime":"0","summary":"截至2025年12月22日收盘，睿智医药报收于9.83元，较前一交易日上涨0.2%，最新总市值为48.95亿元。该股当日开盘9.84元，最高9.86元，最低9.73元，成交额达5021.27万元，换手率为1.08%。公司近日发布公告称，关联方江门市安欣投资有限公司以货币方式向睿智医药全资子公司广东享百年健康科技有限公司增资人民币4,803,921.57元的事项已取得进展。目前，享百年健康科技已完成工商变更登记，并取得广州市越秀区市场监督管理局换发的营业执照。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200034894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300149","BK0216"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772502463798,"stockEarnings":[{"period":"1week","weight":-0.0582},{"period":"1month","weight":-0.0086},{"period":"3month","weight":0.0227},{"period":"6month","weight":-0.1799},{"period":"1year","weight":0.5899},{"period":"ytd","weight":0.0826}],"compareEarnings":[{"period":"1week","weight":0.0246},{"period":"1month","weight":0.0157},{"period":"3month","weight":0.0731},{"period":"6month","weight":0.0968},{"period":"1year","weight":0.2595},{"period":"ytd","weight":0.0539}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"睿智医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"36369人(较上一季度减少1.81%)","perCapita":"13048股","listingDate":"2010-12-22","address":"广东省江门市江海区胜利南路164号","registeredCapital":"49796万元","survey":" 睿智医药科技股份有限公司的主营业务是提供涵盖化学药研发以及生物药从早期发现到开发与规模化生产阶段的一体化服务。公司的主要产品是化学业务、药效药动业务、大分子业务。","listedPrice":28},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"睿智医药(300149)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供睿智医药(300149)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"睿智医药,300149,睿智医药股票,睿智医药股票老虎,睿智医药股票老虎国际,睿智医药行情,睿智医药股票行情,睿智医药股价,睿智医药股市,睿智医药股票价格,睿智医药股票交易,睿智医药股票购买,睿智医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"睿智医药(300149)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供睿智医药(300149)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}